Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Atara Biotherapeutics

Request full access

Developing t-cell therapies

Thousand Oaks, United StatesFounded 2012Biotech & Life Sciences

About Atara Biotherapeutics

Atara Biotherapeutics is a pioneering company in the field of off-the-shelf, allogeneic T cell immunotherapy. Founded in 2012, Atara focuses on developing novel treatments for patients suffering from cancer, autoimmune, and viral diseases. The company operates primarily in the biopharmaceutical sector, targeting a niche market that includes healthcare providers, research institutions, and patients in need of advanced immunotherapy solutions.

Atara's business model revolves around the research, development, and commercialization of its proprietary T cell therapies. These therapies are designed to be readily available 'off-the-shelf,' meaning they do not require customization for each individual patient, which significantly reduces treatment time and costs. The company generates revenue through the sale of its therapies, partnerships with other biopharmaceutical companies, and potential future licensing agreements.

Atara's innovative approach and commitment to advancing medical science have positioned it as a leader in the immunotherapy space. The company continues to present its advancements and key milestones at major healthcare conferences, reflecting its ongoing dedication to improving patient outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014
Outcome tier
Thoroughbred$100M+ revenue

Atara Biotherapeutics in the Thousand Oaks ecosystem

Live from Dealroom

The Atara Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later4 investors entered at this stage

  • 4BIO Capital
  • EcoR1 Capital
  • Redmile Group
  • Adiumentum Capital Management
Team profiled 29 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.9%
🇩🇪 Germany1.1%
2 countries shown
Web traffic by country
5.8K monthly visits
across markets
🇺🇸 United States65.5%
🇮🇳 India25.9%
🇨🇦 Canada10.3%
Top 3 markets shown

Patents

Estimated portfolio value
$10M

10 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Atara Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Atara Biotherapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.